Successful Treatment of Upadacitinib in Prurigo Nodularis: A Case Report and Review of the Literature

Bohui Li,1 Wo Yao,1 Ran Diao,1 Boyun Yang,1 Yongfang Wang,1 Ting Li,1 Liuya Ge,2 Huiying Wang1 1Department of Allergy and Clinical Immunology, The Second Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou, Zhejiang Province, 310009, People’s Republic of China; 2Outpatient Care D...

Full description

Saved in:
Bibliographic Details
Main Authors: Li B, Yao W, Diao R, Yang B, Wang Y, Li T, Ge L, Wang H
Format: Article
Language:English
Published: Dove Medical Press 2025-05-01
Series:International Medical Case Reports Journal
Subjects:
Online Access:https://www.dovepress.com/successful-treatment-of-upadacitinib-in-prurigo-nodularis-a-case-repor-peer-reviewed-fulltext-article-IMCRJ
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1850157484040257536
author Li B
Yao W
Diao R
Yang B
Wang Y
Li T
Ge L
Wang H
author_facet Li B
Yao W
Diao R
Yang B
Wang Y
Li T
Ge L
Wang H
author_sort Li B
collection DOAJ
description Bohui Li,1 Wo Yao,1 Ran Diao,1 Boyun Yang,1 Yongfang Wang,1 Ting Li,1 Liuya Ge,2 Huiying Wang1 1Department of Allergy and Clinical Immunology, The Second Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou, Zhejiang Province, 310009, People’s Republic of China; 2Outpatient Care Department, The Second Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou, Zhejiang Province, 310009, People’s Republic of ChinaCorrespondence: Huiying Wang, Department of Allergy and Clinical Immunology, The Second Affiliated Hospital of Zhejiang University School of Medicine, 88 Jiefang Road, Shangcheng District, Hangzhou, Zhejiang Province, 310009, People’s Republic of China, Email marywang@zju.edu.cnBackground: Prurigo nodularis (PN), while rare, presents significant clinical challenges due to its diverse pathogenesis and presentation. Effective therapy recommendations for PN remain limited. Upadacitinib, an oral highly selective type 1 Janus-associated kinase (JAK, Intracellular tyrosine kinases that phosphorylate cytokine receptors). Inhibitor plays an excellent role in alleviating itching in atopic dermatitis (AD). This is a report on the treatment of PN with upadacitinib, which offers a new option for refractory PN.Case Presentation: We share our successful treatment experience of upadacitinib on a 43-year-old female patient with refractory PN failing to conventional therapies. She showed significant improvement at the follow-up visits and no obvious adverse effects happened. We also reviewed published case reports of PN patients and PN-related review researches and made a comprehensive discussion of the potential mechanism of JAK1 inhibitors in treating PN.Conclusion: Upadacitinib may be a safe and potent alternative for patients with refractory PN.Keywords: prurigo nodularis, upadacitinib, janus kinase inhibitor, immunotherapy, dermatology
format Article
id doaj-art-0258ef749a794c8a9862a3eb95bca5b7
institution OA Journals
issn 1179-142X
language English
publishDate 2025-05-01
publisher Dove Medical Press
record_format Article
series International Medical Case Reports Journal
spelling doaj-art-0258ef749a794c8a9862a3eb95bca5b72025-08-20T02:24:08ZengDove Medical PressInternational Medical Case Reports Journal1179-142X2025-05-01Volume 18Issue 1637644103387Successful Treatment of Upadacitinib in Prurigo Nodularis: A Case Report and Review of the LiteratureLi B0Yao W1Diao R2Yang B3Wang Y4Li T5Ge L6Wang H7Department of Allergy and Clinical ImmunologyDepartment of Allergy and Clinical ImmunologyDepartment of Allergy and Clinical ImmunologyDepartment of Allergy and Clinical ImmunologyDepartment of Allergy and Clinical ImmunologyDepartment of Allergy and Clinical ImmunologyOutpatient Care DepartmentDepartment of Allergy and Clinical ImmunologyBohui Li,1 Wo Yao,1 Ran Diao,1 Boyun Yang,1 Yongfang Wang,1 Ting Li,1 Liuya Ge,2 Huiying Wang1 1Department of Allergy and Clinical Immunology, The Second Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou, Zhejiang Province, 310009, People’s Republic of China; 2Outpatient Care Department, The Second Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou, Zhejiang Province, 310009, People’s Republic of ChinaCorrespondence: Huiying Wang, Department of Allergy and Clinical Immunology, The Second Affiliated Hospital of Zhejiang University School of Medicine, 88 Jiefang Road, Shangcheng District, Hangzhou, Zhejiang Province, 310009, People’s Republic of China, Email marywang@zju.edu.cnBackground: Prurigo nodularis (PN), while rare, presents significant clinical challenges due to its diverse pathogenesis and presentation. Effective therapy recommendations for PN remain limited. Upadacitinib, an oral highly selective type 1 Janus-associated kinase (JAK, Intracellular tyrosine kinases that phosphorylate cytokine receptors). Inhibitor plays an excellent role in alleviating itching in atopic dermatitis (AD). This is a report on the treatment of PN with upadacitinib, which offers a new option for refractory PN.Case Presentation: We share our successful treatment experience of upadacitinib on a 43-year-old female patient with refractory PN failing to conventional therapies. She showed significant improvement at the follow-up visits and no obvious adverse effects happened. We also reviewed published case reports of PN patients and PN-related review researches and made a comprehensive discussion of the potential mechanism of JAK1 inhibitors in treating PN.Conclusion: Upadacitinib may be a safe and potent alternative for patients with refractory PN.Keywords: prurigo nodularis, upadacitinib, janus kinase inhibitor, immunotherapy, dermatologyhttps://www.dovepress.com/successful-treatment-of-upadacitinib-in-prurigo-nodularis-a-case-repor-peer-reviewed-fulltext-article-IMCRJPrurigo nodularisUpadacitinibJanus kinase inhibitorImmunotherapyDermatology
spellingShingle Li B
Yao W
Diao R
Yang B
Wang Y
Li T
Ge L
Wang H
Successful Treatment of Upadacitinib in Prurigo Nodularis: A Case Report and Review of the Literature
International Medical Case Reports Journal
Prurigo nodularis
Upadacitinib
Janus kinase inhibitor
Immunotherapy
Dermatology
title Successful Treatment of Upadacitinib in Prurigo Nodularis: A Case Report and Review of the Literature
title_full Successful Treatment of Upadacitinib in Prurigo Nodularis: A Case Report and Review of the Literature
title_fullStr Successful Treatment of Upadacitinib in Prurigo Nodularis: A Case Report and Review of the Literature
title_full_unstemmed Successful Treatment of Upadacitinib in Prurigo Nodularis: A Case Report and Review of the Literature
title_short Successful Treatment of Upadacitinib in Prurigo Nodularis: A Case Report and Review of the Literature
title_sort successful treatment of upadacitinib in prurigo nodularis a case report and review of the literature
topic Prurigo nodularis
Upadacitinib
Janus kinase inhibitor
Immunotherapy
Dermatology
url https://www.dovepress.com/successful-treatment-of-upadacitinib-in-prurigo-nodularis-a-case-repor-peer-reviewed-fulltext-article-IMCRJ
work_keys_str_mv AT lib successfultreatmentofupadacitinibinprurigonodularisacasereportandreviewoftheliterature
AT yaow successfultreatmentofupadacitinibinprurigonodularisacasereportandreviewoftheliterature
AT diaor successfultreatmentofupadacitinibinprurigonodularisacasereportandreviewoftheliterature
AT yangb successfultreatmentofupadacitinibinprurigonodularisacasereportandreviewoftheliterature
AT wangy successfultreatmentofupadacitinibinprurigonodularisacasereportandreviewoftheliterature
AT lit successfultreatmentofupadacitinibinprurigonodularisacasereportandreviewoftheliterature
AT gel successfultreatmentofupadacitinibinprurigonodularisacasereportandreviewoftheliterature
AT wangh successfultreatmentofupadacitinibinprurigonodularisacasereportandreviewoftheliterature